In a switch, Merck CEO signals he’s in a deal-making frame of mind
Over the last few years, Merck’s big R&D group has been concentrating heavily on its PD-1 superstar Keytruda, for obvious reasons. After jumping in as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
